Zenas Biopharma Inc (NASDAQ: ZBIO)’s stock price has gone rise by 13.24 in comparison to its previous close of 7.25, however, the company has experienced a 17.96% increase in its stock price over the last five trading days. globenewswire.com reported 2025-02-05 that – Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025- -Topline results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (INDIGO) expected year-end 2025- – Enrollment of Phase 2 Trial in Systemic Lupus Erythematosus (SunStone) expected to be completed in 2025- – Out-licensed greater-China anti-IGF-1R Thyroid Eye Disease programs to Zai Lab – WALTHAM, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced its 2024 accomplishments, outlined its key business objectives for 2025 and announced preliminary unaudited cash balance as of year-end 2024.
Is It Worth Investing in Zenas Biopharma Inc (NASDAQ: ZBIO) Right Now?
Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ZBIO is 10.71M, and at present, short sellers hold a 31.87% of that float. On March 13, 2025, the average trading volume of ZBIO was 264.53K shares.
ZBIO’s Market Performance
ZBIO’s stock has seen a 17.96% increase for the week, with a 8.45% rise in the past month and a -24.33% fall in the past quarter. The volatility ratio for the week is 12.06%, and the volatility levels for the past 30 days are at 9.79% for Zenas Biopharma Inc The simple moving average for the past 20 days is 15.47% for ZBIO’s stock, with a -35.87% simple moving average for the past 200 days.
Analysts’ Opinion of ZBIO
Many brokerage firms have already submitted their reports for ZBIO stocks, with Wolfe Research repeating the rating for ZBIO by listing it as a “Outperform.” The predicted price for ZBIO in the upcoming period, according to Wolfe Research is $19 based on the research report published on February 04, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ZBIO reach a price target of $30. The rating they have provided for ZBIO stocks is “Buy” according to the report published on December 16th, 2024.
Rodman & Renshaw gave a rating of “Buy” to ZBIO, setting the target price at $34 in the report published on November 05th of the previous year.
ZBIO Trading at 5.93% from the 50-Day Moving Average
After a stumble in the market that brought ZBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.72% of loss for the given period.
Volatility was left at 9.79%, however, over the last 30 days, the volatility rate increased by 12.06%, as shares surge +12.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.31% lower at present.
During the last 5 trading sessions, ZBIO rose by +17.96%, in comparison to the 20-day moving average, which settled at $7.11. In addition, Zenas Biopharma Inc saw 0.24% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZBIO starting from MOULDER LEON O JR, who purchase 25,000 shares at the price of $6.67 back on Feb 18 ’25. After this action, MOULDER LEON O JR now owns 266,155 shares of Zenas Biopharma Inc, valued at $166,750 using the latest closing price.
Xiao Ting, the Director of Zenas Biopharma Inc, purchase 10,000 shares at $7.76 during a trade that took place back on Feb 07 ’25, which means that Xiao Ting is holding 47,000 shares at $77,600 based on the most recent closing price.
Stock Fundamentals for ZBIO
The total capital return value is set at -0.37.
Based on Zenas Biopharma Inc (ZBIO), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -251.35.
Currently, EBITDA for the company is -163.89 million with net debt to EBITDA at 2.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.21.
Conclusion
To sum up, Zenas Biopharma Inc (ZBIO) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
